Asset Management One Co. Ltd. Acquires 39,076 Shares of Boston Scientific Corporation (NYSE:BSX)

Asset Management One Co. Ltd. increased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 5.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 735,200 shares of the medical equipment provider's stock after buying an additional 39,076 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Boston Scientific were worth $74,167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Parnassus Investments LLC lifted its position in Boston Scientific by 0.7% in the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock valued at $1,327,000 after acquiring an additional 97 shares in the last quarter. Baldwin Investment Management LLC raised its stake in shares of Boston Scientific by 1.2% in the fourth quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock worth $781,000 after purchasing an additional 102 shares during the last quarter. Evergreen Capital Management LLC lifted its holdings in shares of Boston Scientific by 1.7% during the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock valued at $565,000 after purchasing an additional 106 shares in the last quarter. PDS Planning Inc boosted its position in shares of Boston Scientific by 1.5% during the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock valued at $668,000 after buying an additional 113 shares during the last quarter. Finally, Paladin Wealth LLC increased its holdings in Boston Scientific by 1.6% in the 1st quarter. Paladin Wealth LLC now owns 7,156 shares of the medical equipment provider's stock worth $722,000 after buying an additional 113 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,572 shares of Boston Scientific stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the transaction, the executive vice president now directly owns 178,342 shares of the company's stock, valued at approximately $18,347,824.96. The trade was a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 411,970 shares of company stock valued at $42,406,693 in the last three months. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

Boston Scientific stock traded up $0.19 during mid-day trading on Wednesday, hitting $104.31. The stock had a trading volume of 5,667,756 shares, compared to its average volume of 6,584,472. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $107.17. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $154.32 billion, a P/E ratio of 76.14, a P/E/G ratio of 2.65 and a beta of 0.68. The firm's 50 day moving average is $102.14 and its 200 day moving average is $99.29.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The business's quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.56 earnings per share. On average, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Citigroup reaffirmed a "buy" rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Evercore ISI increased their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Morgan Stanley boosted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Finally, BTIG Research reissued a "buy" rating and set a $124.00 price target on shares of Boston Scientific in a report on Wednesday, April 23rd. Twenty-two analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $116.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.